The Multifaceted Role of Plasminogen in Cancer.
Anoikis
/ genetics
Autophagy
Cell Survival
Cellular Senescence
Drug Resistance, Neoplasm
/ genetics
Exosomes
/ metabolism
Extracellular Matrix
/ metabolism
Humans
Neoplasm Metastasis
/ drug therapy
Neoplasms
/ drug therapy
Plasminogen
/ antagonists & inhibitors
Plasminogen Inactivators
/ genetics
Signal Transduction
/ genetics
LRP1
anoikis
cancer
drug resistance
exosomes
metastasis
plasminogen
premetastatic niche
senescence
uPAR
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Feb 2021
25 Feb 2021
Historique:
received:
28
01
2021
revised:
17
02
2021
accepted:
19
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Fibrinolytic factors like plasminogen, tissue-type plasminogen activator (tPA), and urokinase plasminogen activator (uPA) dissolve clots. Though mere extracellular-matrix-degrading enzymes, fibrinolytic factors interfere with many processes during primary cancer growth and metastasis. Their many receptors give them access to cellular functions that tumor cells have widely exploited to promote tumor cell survival, growth, and metastatic abilities. They give cancer cells tools to ensure their own survival by interfering with the signaling pathways involved in senescence, anoikis, and autophagy. They can also directly promote primary tumor growth and metastasis, and endow tumor cells with mechanisms to evade myelosuppression, thus acquiring drug resistance. In this review, recent studies on the role fibrinolytic factors play in metastasis and controlling cell-death-associated processes are presented, along with studies that describe how cancer cells have exploited plasminogen receptors to escape myelosuppression.
Identifiants
pubmed: 33669052
pii: ijms22052304
doi: 10.3390/ijms22052304
pmc: PMC7956603
pii:
doi:
Substances chimiques
Plasminogen Inactivators
0
Plasminogen
9001-91-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K0885
Organisme : Japan Society for the Promotion of Science
ID : 18K08657
Organisme : Uehara Memorial Foundation
ID : B.H.
Organisme : Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering
ID : KH
Organisme : Thermo Scientific
ID : KH
Organisme : Okinaka Memorial Institute for Medical Research
ID : KH
Organisme : Institute of Medical Science, University of Tokyo
ID : KH
Références
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32752135
J Biochem. 2006 Mar;139(3):391-8
pubmed: 16567404
BMC Cancer. 2010 Jun 16;10:294
pubmed: 20553606
J Cell Sci. 2017 Oct 1;130(19):3272-3281
pubmed: 28794016
Cell. 2016 Apr 21;165(3):631-42
pubmed: 27062928
Nature. 2020 Jul;583(7814):127-132
pubmed: 32555459
Gastroenterology. 2009 Apr;136(4):1379-90, e1-5
pubmed: 19171142
Blood Adv. 2018 May 22;2(10):1054-1065
pubmed: 29752284
Cell. 2012 Nov 21;151(5):1068-82
pubmed: 23142051
Dev Cell. 2019 May 6;49(3):347-360
pubmed: 31063754
Mol Cancer Res. 2017 Jan;15(1):93-105
pubmed: 27760843
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Cells. 2020 May 20;9(5):
pubmed: 32443727
Cell Death Dis. 2019 Jul 15;10(8):539
pubmed: 31308359
J Exp Med. 2005 Sep 19;202(6):739-50
pubmed: 16157686
Elife. 2015 May 08;4:e05914
pubmed: 25955862
J Biol Chem. 1997 Aug 15;272(33):20572-6
pubmed: 9252371
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
J Biol Chem. 1989 Jul 15;264(20):11843-8
pubmed: 2473065
Cell Stem Cell. 2007 Dec 13;1(6):658-70
pubmed: 18371407
J Biol Chem. 2013 Nov 22;288(47):34009-34018
pubmed: 24129569
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Rep. 2018 Aug 7;24(6):1484-1495
pubmed: 30089260
Cell Mol Life Sci. 2015 Dec;72(24):4759-70
pubmed: 26350342
EBioMedicine. 2019 Jan;39:194-206
pubmed: 30611716
Am J Physiol. 1998 Aug;275(2):E321-31
pubmed: 9688635
Blood. 2006 Apr 15;107(8):3408-9
pubmed: 16597598
Blood. 2016 Aug 25;128(8):1063-75
pubmed: 27283026
Blood. 2011 May 12;117(19):5166-77
pubmed: 21411755
Sci Rep. 2020 Apr 30;10(1):7375
pubmed: 32355198
Cell Rep. 2018 Nov 20;25(8):2177-2191.e7
pubmed: 30463014
Oncogene. 2021 Jan;40(2):384-395
pubmed: 33149280
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):172-179
pubmed: 26588878
Pancreas. 2008 Mar;36(2):160-7
pubmed: 18376307
Nat Med. 2001 Nov;7(11):1194-201
pubmed: 11689883
Cell Death Dis. 2017 Oct 26;8(10):e3144
pubmed: 29072683
Blood. 2007 Jun 1;109(11):4793-802
pubmed: 17272502
Int J Oncol. 2018 Jan;52(1):5-18
pubmed: 29115416
J Dermatol Sci. 2017 Oct;88(1):96-102
pubmed: 28669590
Cell Signal. 2020 Nov;75:109761
pubmed: 32861744
Front Pharmacol. 2015 Nov 10;6:271
pubmed: 26617523
J Biol Chem. 2018 Jun 1;293(22):8600-8613
pubmed: 29669808
Cancer Res. 2007 Oct 15;67(20):9817-24
pubmed: 17942912
J Thromb Haemost. 2020 Nov;18(11):2968-2975
pubmed: 32780555
Cell Physiol Biochem. 2018;47(5):1909-1924
pubmed: 29961070
Biomed Pharmacother. 2018 Sep;105:83-94
pubmed: 29852393
J Exp Clin Cancer Res. 2019 Jun 11;38(1):250
pubmed: 31186061
Front Pharmacol. 2015 Jul 27;6:154
pubmed: 26283964
FASEB J. 2019 Mar;33(3):3465-3480
pubmed: 30458112
Trends Cancer. 2020 Oct;6(10):838-857
pubmed: 32482536
Front Oncol. 2018 Feb 12;8:24
pubmed: 29484286
J Biol Chem. 2009 Dec 4;284(49):34045-53
pubmed: 19815552
FASEB J. 2003 Jul;17(10):1301-3
pubmed: 12738809